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Autoinflammatory diseases are rare disorders secondary
to mutation of genes involved in the regulation of innate
immunity. The main limitation to a better knowledge of
Autoinflammatory diseases is related to the extreme
fragmentation of the diagnosed cases that are spread over
different centers and countries. The general aim of the
Eurofever Project was to build an international registry
on Autoinflammatory diseases.
A web-based registry collecting baseline and cross-
sectional clinical information on Autoinflammatory dis-
eases is available in the member area of the PRINTO
web-site (www.printo.it). The registry is open to all
pediatric and adult Centers with a specific interest in
Autoinflammatory diseases. The following monogenic
autoinflammatory diseases were considered: Familial
Mediterranean Fever (FMF), Cryopyrin-associated periodic
syndromes (CAPS), TNF receptor-associated periodic syn-
drome (TRAPS), mevalonate kinase deficiency (MKD),
Blau syndrome, pyogenic arthritis, pioderma and acne
(PAPA) syndrome, deficiency of IL-1 receptor antagonist
(DIRA), NLRP12-mediated periodic fever. Information on
CRMO, Behçet’s disease, PFAPA and undefined periodic
fevers were also collected.
2916 patients, from 95 centers in 53 countries, have
been enrolled in the registry during the first 36 months.
Baseline demographic data (country of residence, disease
onset, disease duration, mutations, family history ect)
from all patients are now available. In 2275 (81%) com-
plete information on clinical manifestations and
responses to treatments is also available. The disease
distribution of enrolled patients is: FMF 787 (621 with
complete clinical data); TRAPS 237 (211 with complete
clinical data); CAPS 207 (186 with complete clinical
data); MKD 153 (133 with complete clinical data); Blau
syndrome 62 (21 with complete clinical data); PAPA 19
(18 with complete clinical data); NLRP-12 mediated per-
iodic fever 8 (6 with complete clinical data); DIRA and
Majeed 3 and 2 patients, respectively (all with complete
clinical data).
Among multifactorial autoinflammatory diseases:
PFAPA 564 (402 with complete clinical data); CRMO
392 (370 with complete clinical data); pediatric Behçet
disease 84 (68 with complete clinical data) and 205
patients with undefined periodic fever (174 with complete
clinical data).
So far 8 papers involving 56 different authors and
32 centers have been published in high-rank international
journals and other papers are in preparation.
A large registry of patients with Autoinflammatory
diseases is available and, despite the expiring of the initial
grant, the enrolment is still ongoing with an increasing
number of centers involved. Eurofever represents a good
example of how a disease-oriented registry can provide
relevant scientific answers to many unknown clinical
aspects of ultra-rare diseases. This aspects was the main
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